Dr Shachi Patel
About Dr Shachi Patel
Dr. Shachi Patel is an Associate Principal at ClearView Healthcare Partners, specializing in commercialization and innovation strategies in Cell and Gene Therapy. She has a strong background in R&D and growth strategy within the life sciences industry, with previous roles at notable organizations including EY-Parthenon and GlaxoSmithKline.
Work at ClearView Healthcare Partners
Dr. Shachi Patel serves as an Associate Principal at ClearView Healthcare Partners, a position she has held since 2022. In this role, she focuses on strategy consulting within the life sciences sector, leveraging her extensive experience in commercialization and innovation strategies. Dr. Patel's expertise is particularly relevant to the pharmaceutical, biotech, and medical device industries, with a specific emphasis on European markets.
Education and Expertise
Dr. Patel earned her Doctor of Philosophy (PhD) in Pathology from the University of Cambridge, where she studied from 2011 to 2015. Prior to this, she obtained a Bachelor of Science with Honours (BSc Hons.) in Pharmacology from King's College London, completing her studies from 2007 to 2011. Her academic background supports her expertise in commercialization and innovation strategies, especially in Cell and Gene Therapy (C>).
Background in Research and Consulting
Dr. Patel began her career as a Research Associate at the University of Cambridge, where she worked from 2011 to 2016. Following this, she transitioned into consulting roles, starting with Alcimed as a Consultant for eight months in 2016. She then joined Navigant as a Senior Consultant from 2016 to 2018, before taking on a role at EY-Parthenon as an Associate Director from 2018 to 2022. This progression highlights her strong background in research and consulting within the life sciences industry.
Professional Experience at GlaxoSmithKline
Dr. Patel completed an Industrial Placement at GlaxoSmithKline from 2009 to 2010. This experience provided her with foundational insights into the pharmaceutical industry, which she has built upon throughout her career. Her time at GlaxoSmithKline contributed to her understanding of the complexities involved in drug development and commercialization.